FDA Panel Nixes Naproxcinod for Osteoarthritis
In a joint meeting, the US Food and Drug Administration’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee today failed to endorse the approval of the novel anti-inflammatory drug naproxcinod for the relief of signs and symptoms of osteoarthritis, sending the drug’s French sponsor back to the drawing board for additional safety [...]
